Cellphmed
Cellphmed identifies novel RNA biomarkers from previously unexplored regions of the genome to enable earlier, more targeted cancer diagnostics and immunotherapy target discovery. The company offers a bioinformatics platform built on proprietary tools that analyze the transposable transcriptome and noncanonical RNA signals. It applies machine learning and AI to prioritize millions of candidate biomarkers for validation. Cellphmed targets biotech and pharmaceutical R&D teams and clinical researchers working in oncology and related fields.
Cellphmed
Cellphmed identifies novel RNA biomarkers from previously unexplored regions of the genome to enable earlier, more targeted cancer diagnostics and immunotherapy target discovery. The company offers a bioinformatics platform built on proprietary tools that analyze the transposable transcriptome and noncanonical RNA signals. It applies machine learning and AI to prioritize millions of candidate biomarkers for validation. Cellphmed targets biotech and pharmaceutical R&D teams and clinical researchers working in oncology and related fields.